Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jonasch

Showing results (21-30 of 271) with videos related to

Pageof 28
Sort By:
Future Oncology (London, England)|November 3, 2011
Axitinib in the treatment of metastatic renal cell carcinomaThai H Ho, Eric Jonasch
Cancer Journal (Sudbury, Mass.)|October 7, 2008
Adjuvant and neoadjuvant therapy in renal cell carcinomaEric Jonasch, Nizar M Tannir
Oncotarget|March 23, 2019
SET-ing the stage for PI3Kβ inhibitor sensitivity in clear cell renal cell carcinomaPatrick G Pilié, Eric Jonasch
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|January 4, 2022
Sunitinib-Related Osteonecrosis of the External Auditory Canal: Case ReportArturo Eguia, Eric Jonasch, Paul Gidley
Current Clinical Pharmacology|August 11, 2011
Adjuvant and neoadjuvant therapy in renal cell carcinomaMichel Choueiri, Nizar Tannir, Eric Jonasch
BMJ (Clinical Research Ed.)|November 12, 2014
Renal cell carcinomaEric Jonasch, Jianjun Gao, W Kimryn Rathmell
Medscience|May 26, 2026
Essential genetic mutations impair DNA damage repair and modulate tumor immune microenvironment in ccRCCHongchao He, Xian-De Liu, Eric Jonasch
Molecular & Cellular Oncology|June 17, 2016
Autophagy degrades hypoxia inducible factorsAdela DePavia, Eric Jonasch, Xian-De Liu
Seminars in Oncology|August 27, 2013
Molecular markers to predict response to therapyJesus Garcia-Donas, Cristina Rodriguez-Antona, Eric Jonasch
Nature Reviews. Nephrology|November 4, 2020
Clear cell renal cell carcinoma ontogeny and mechanisms of lethalityEric Jonasch, Cheryl Lyn Walker, W Kimryn Rathmell
Pageof 28

Showing results (21-30 of 271) with videos related to

Sort By:
Pageof 28
Future Oncology (London, England)|November 3, 2011
Axitinib in the treatment of metastatic renal cell carcinomaThai H Ho, Eric Jonasch
Cancer Journal (Sudbury, Mass.)|October 7, 2008
Adjuvant and neoadjuvant therapy in renal cell carcinomaEric Jonasch, Nizar M Tannir
Oncotarget|March 23, 2019
SET-ing the stage for PI3Kβ inhibitor sensitivity in clear cell renal cell carcinomaPatrick G Pilié, Eric Jonasch
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|January 4, 2022
Sunitinib-Related Osteonecrosis of the External Auditory Canal: Case ReportArturo Eguia, Eric Jonasch, Paul Gidley
Current Clinical Pharmacology|August 11, 2011
Adjuvant and neoadjuvant therapy in renal cell carcinomaMichel Choueiri, Nizar Tannir, Eric Jonasch
BMJ (Clinical Research Ed.)|November 12, 2014
Renal cell carcinomaEric Jonasch, Jianjun Gao, W Kimryn Rathmell
Medscience|May 26, 2026
Essential genetic mutations impair DNA damage repair and modulate tumor immune microenvironment in ccRCCHongchao He, Xian-De Liu, Eric Jonasch
Molecular & Cellular Oncology|June 17, 2016
Autophagy degrades hypoxia inducible factorsAdela DePavia, Eric Jonasch, Xian-De Liu
Seminars in Oncology|August 27, 2013
Molecular markers to predict response to therapyJesus Garcia-Donas, Cristina Rodriguez-Antona, Eric Jonasch
Nature Reviews. Nephrology|November 4, 2020
Clear cell renal cell carcinoma ontogeny and mechanisms of lethalityEric Jonasch, Cheryl Lyn Walker, W Kimryn Rathmell
Pageof 28